Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

Is the AstraZeneca share price still good value at £10?

The AstraZeneca share price has been a top FTSE 100 performer in recent years. Roland Head asks if hes too…

Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca

Todays Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and…

What Are Whales Doing With AstraZeneca

Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We…

Mistake To Recommend COVID-19 Vaccines For All Children: Top Danish Health Official

Mistake To Recommend COVID-19 Vaccines For All Children: Top Danish Health Official …

AstraZeneca: Phase III Data Show Significant Copper Mobilization From Tissues With ALXN1840

LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) said the detailed results from the positive FoCus phase III trial in Wilson…

Astrazeneca (AZN) Gains As Market Dips: What You Should Know

In the latest trading session, Astrazeneca (AZN) closed at $63.55, marking a +1.15% move from the previous day....…

ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively

ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively...…

Short Volatility Alert: AstraZeneca PLC

On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up…

AstraZeneca, Daiichi Sankyo Enhertu gets EMA review for breast cancer subtype

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca, Biocartis team up to develop companion diagnostic for lung cancer drug Tagrisso

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biocartis In Deal With AstraZeneca To Develop Companion Diagnostic Test For Tagrisso

LONDON (dpa-AFX) - Biocartis Group NV, a Belgium-based molecular diagnostics company, announced Wednesday that it has entered into an agreement…

Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®

PRESS RELEASE: 22 June 2022, 07:00 CEST...…

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

The agreement expands on the existing collaboration between the two parties to reinforce the position of Abu Dhabi as a…

AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year

U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for…

AstraZeneca hails phase III success of drug for rare disease amyloid polyneuropathy

Um den gesamten Artikel unter proactiveinvestors.com.au zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K ASTRAZENECA PLC For: Jun 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 2-AstraZeneca, Ionis eye U.S. approval after positive trial data

...(Adds detail, background) By Natalie Grover LONDON, June 21 (Reuters......…

AstraZeneca/Ionis rare disease drug shows positive data in late stage study

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca and Ionis drug for rare disease achieves positive trial data

...LONDON (Reuters) - An interim analysis of AstraZeneca and partner......…

AstraZeneca Posts Positive Interim Data In Eplontersen Phase III Trial In ATTRv-PN

LONDON (dpa-AFX) - British drug major AstraZeneca PLC (AZN.L, AZN) announced Tuesday that Eplontersen met co-primary and secondary endpoints in…

BRIEF-Astrazeneca Says Eplontersen Ph III Trial Met Co-Primary Endpoints

...June 21 (Reuters) - AstraZeneca PLC: * ASTRAZENECA PLC - EPLONTERSEN......…

AstraZeneca Gets Positive Results From Phase 3 Trial of Eplontersen

AstraZeneca Gets Positive Results From Phase 3 Trial of Eplontersen...…

Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

- Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN - Eplontersen demonstrated a favorable safety…

Eplontersen Ph III trial met co-primary endpoints

21 June 2022 07:00 BST Eplontersen met co-primary and secondary endpoints in interim analysis of the NEURO-TTRansform Phase III trial for hereditary…

Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout

Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it....…

Volkswagen, Traton, AstraZeneca, Mereo Biopharma und Aareal Bank – Der kompakte Tagesüberblick

Der DAX unternimmt nach dem gestrigen Kurseinbruch heute einen Stabilisierungsversuch und erobert auch die 13.000er-Marke zurück. Auch in den USA starten…

Astrazeneca prüft Übernahmeangebot für Mereo Biopharma - Zeitung

LONDON (Dow Jones)--Astrazeneca erwägt nach einem Bericht der britischen Zeitung Times die Vorlage eines Übernahmeangebotes für das in London ansässige…

AstraZeneca weighing bid for Mereo BioPharma: report

AstraZeneca is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma , The Times reported without attribution. AstraZeneca already…

Astrazeneca (AZN) Gains As Market Dips: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $60.86, moving +0.48% from the previous trading session....…

Is AstraZeneca the best FTSE 100 stock to buy for future growth?

FTSE 100 stock AstraZeneca was in the spotlight during the pandemic, but theres more to the pharma giants business than…

UBS downgrades AstraZeneca, says 2022 now more about commercial execution

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca downgraded by UBS on lack of catalysts until 2023

Um den gesamten Artikel unter proactiveinvestors.com.au zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca Neutral

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Astrazeneca von "Buy" auf "Neutral" abgestuft und das Kursziel von 10500…

Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines

-- Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™ (Sinovac Inactivated Vaccine), Comirnaty®…

FIVE at FIVE: De Pfeffel kerfuffle; Musk in handbrake turn; Countryside Partnerships under siege; AstraZeneca finds market hard to please

Um den gesamten Artikel unter proactiveinvestors.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…